Celltrion expands Japan push with SteQeyma IV launch
- Source
- The Korea Herald - Business
- Source link
- https://www.koreaherald.com/article/10848116
- Published
- 2026-08-21 13:52:50
- Discovered by ProcIntel
- 2026-08-21 08:34:50
- Category
- Procurement & Supply Chain News
- Geography
- South Korea
- Organisations
- —
- Review status
- Pending
- Record type
- REAL
Summary
Celltrion said Friday it has launched the intravenous formulation of SteQeyma for autoimmune diseases in Japan. Celltrion launched the IV formulation about four months after receiving approval from Japan’s Ministry of Health, Labour and Welfare in April. In addition to its existing indications for psoriasis and psoriatic arthritis, the product now also covers Crohn’s disease, significantly expanding its treatment scope. Celltrion’s Japanese subsidiary plans to leverage its sales expertise built
Procurement Relevance Gate
- supplier_or_company_impact (weight 12) — matched on "subsidiary"
- geographic_exposure (weight 8) — matched on "1 linked geography"
Initial Signal Assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically-computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
- Initial Significance
- 1 · Low (15.0/100)
- Initial Confidence
- 1 · Very Low (12.5/100)
- Data sufficiency Whether enough structured evidence exists to trust this Signal's Initial Confidence reading. 'Sufficient' has no cap; 'Partial' and 'Insufficient' cap Confidence until more evidence is available; 'Not Assessed' means the Signal did not pass the Relevance Gate.
- Insufficient
- Strongest contributor
- Procurement Impact
- Limiting factor
- Impact-Scale Specificity
Initial Significance Low (15.0/100). Strongest contributor: Procurement Impact (6.0/30 points). Limiting factor: Impact-Scale Specificity (0.0/10 points). Initial Confidence Very Low (12.5/100, data sufficiency: Insufficient). Strongest contributor: Source Authority (12.0/40 points). Limiting factor: Specificity (0.0/20 points).
- No likely Event type matched; a low contextual baseline was applied.
- No eligible (non-geographic, non-fictional) entities were linked to this Signal.
- no confidence-specificity evidence (actor entity, date, quantified value, or concrete verb)
- no matched Event type
- no actor entities (only attribution/metadata, if any)
- no actor content-derived geography
- single source only
- Entities were mentioned as context or document attribution rather than as actors in the reported development, so they did not increase Initial Confidence.
- Geographies were mentioned only in diplomatic reaction, commentary or background context rather than as the actor, event location or affected party in the reported development, so they did not increase Initial Confidence.
- Only source-level geography metadata was available.
- Source metadata did not contribute to Initial Confidence.
- 1 distinct hedging pattern(s) matched (capped at 20).
Methodology signal_scoring_v1 — calculated 2026-08-21 08:34:50.